Zimmer Biomet (NYSE:ZBH) Releases FY 2026 Earnings Guidance

Zimmer Biomet (NYSE:ZBH) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 8.470-8.590 for the period, compared to the consensus EPS estimate of 8.480. The company issued revenue guidance of $8.6 billion-$8.6 billion, compared to the consensus revenue estimate of $8.5 billion.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded down $0.99 during mid-day trading on Friday, hitting $96.20. 905,910 shares of the company traded hands, compared to its average volume of 2,328,983. Zimmer Biomet has a one year low of $79.12 and a one year high of $108.29. The stock has a market cap of $18.61 billion, a price-to-earnings ratio of 23.43, a price-to-earnings-growth ratio of 2.88 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.69. The stock has a fifty day moving average price of $89.89 and a 200-day moving average price of $90.09.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same period in the prior year, the company earned $2.07 EPS. The company’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts predict that Zimmer Biomet will post 8.5 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were given a $0.24 dividend. The ex-dividend date was Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s payout ratio is presently 24.94%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Zacks Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, July 27th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday. Truist Financial raised their target price on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research note on Thursday. UBS Group restated a “buy” rating and set a $120.00 price target on shares of Zimmer Biomet in a report on Thursday. Finally, JPMorgan Chase & Co. lowered their price target on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $104.00.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.28% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several large investors have recently made changes to their positions in ZBH. AQR Capital Management LLC increased its position in Zimmer Biomet by 276.6% during the second quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after acquiring an additional 955,284 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Zimmer Biomet by 28.6% during the 4th quarter. Victory Capital Management Inc. now owns 2,475,768 shares of the medical equipment provider’s stock valued at $223,529,000 after purchasing an additional 551,005 shares during the period. Schonfeld Strategic Advisors LLC increased its position in shares of Zimmer Biomet by 3,633.7% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 464,250 shares of the medical equipment provider’s stock valued at $45,729,000 after purchasing an additional 451,816 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Zimmer Biomet by 30.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 1,544,646 shares of the medical equipment provider’s stock worth $139,054,000 after purchasing an additional 360,624 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Zimmer Biomet by 10.6% in the 4th quarter. Invesco Ltd. now owns 3,361,075 shares of the medical equipment provider’s stock worth $302,228,000 after purchasing an additional 322,689 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.